PLPL — Plandai Biotechnology Share Price
Last trade - 00:00- $0.89m
- $15.42m
- $0.30m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.63 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -871.39% | ||
Financial Summary
| Year End 30th Jun | Unit | 2012 | 2013 | 2014 | 2015 | 2016 | 2017E | 2018E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.07 | 0.36 | 0.27 | 0.09 | 0.3 | n/a | n/a | -47.04% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Plandai Biotechnology, Inc. is a biotech company, which is focused on the production of botanical extracts for the nutraceutical and pharmaceutical industries. The Company grows the green tea used in its products on a 3,000-hectare estate in the Mpumalanga region of South Africa. Its marketed product, Phytofare Catechin Complex, is a green-tea-derived extract that has multiple potential wellness applications. It caters to airline flights and operated coffee shops, lounges and gift shops at airports, and other facilities located in Florida, Alabama, and Georgia. Its airline catering services include the preparation of meals in kitchens located at, or adjacent to, airports and the distribution of meals and beverages for service on commercial airline flights. The Company also provides certain ancillary services, including the preparation of beverage service carts, the unloading and cleaning of plates, utensils and other accessories arriving on incoming aircraft, and other.
Directors
- Roger Baylis-Duffield CHM (71)
- Callum Cottrell Duffield PRE (31)
- Ezra Jones VPR
- Jamen Shively VPR (46)
- Daron Duffield DRC (64)
- Brian Johnson DRC (59)
- Last Annual
- June 30th, 2016
- Last Interim
- September 30th, 2016
- Incorporated
- February 24th, 2004
- Public Since
- December 10th, 2001
- No. of Employees
- 100
- Sector
- Holding Companies
- Industry
- Financials
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 8,889,034,371
- Address
- 4811 49TH STREET, SAN DIEGO, 92115
- Web
- http://www.plandaibiotech.com/
- Phone
- +1 6192399034
- Auditors
- Not Available
Upcoming Events for PLPL
Similar to PLPL
1399 Internet Technology Application
Pink Sheets on Nasdaq
3D Pioneer Systems
Pink Sheets on Nasdaq
9 Meters Biopharma
Pink Sheets on Nasdaq
Absolute Health and Fitness
Pink Sheets on Nasdaq
ACC Aviation Holdings
Pink Sheets on Nasdaq
FAQ
As of Today at 23:08 UTC, shares in Plandai Biotechnology are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Plandai Biotechnology last closed at $0.00 and the price had moved by -66.67% over the past 365 days. In terms of relative price strength the Plandai Biotechnology share price has underperformed the S&P500 Index by -72.15% over the past year.
There is no consensus recommendation for this security.
Find out morePlandai Biotechnology does not currently pay a dividend.
Plandai Biotechnology does not currently pay a dividend.
Plandai Biotechnology does not currently pay a dividend.
To buy shares in Plandai Biotechnology you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Plandai Biotechnology had a market capitalisation of $0.89m.
Here are the trading details for Plandai Biotechnology:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: PLPL
Based on an overall assessment of its quality, value and momentum Plandai Biotechnology is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Plandai Biotechnology. Over the past six months, its share price has underperformed the S&P500 Index by -5.82%.
As of the last closing price of $0.00, shares in Plandai Biotechnology were trading -57.29% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Plandai Biotechnology PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Plandai Biotechnology's management team is headed by:
- Roger Baylis-Duffield - CHM
- Callum Cottrell Duffield - PRE
- Ezra Jones - VPR
- Jamen Shively - VPR
- Daron Duffield - DRC
- Brian Johnson - DRC